Local inflammation caused by a monoclonal antibody that blocks the function of the rat membrane inhibitor of C3 convertase

被引:0
|
作者
Nishikawa, K
Matsuo, S
Okada, N
Morgan, BP
Okada, H
机构
[1] NAGOYA CITY UNIV,SCH MED,DEPT BIOL MOLEC,NAGOYA,AICHI 467,JAPAN
[2] NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 3,NAGOYA,AICHI 466,JAPAN
[3] UNIV WALES COLL MED,DEPT BIOCHEM MED,CARDIFF CF4 4XN,S GLAM,WALES
来源
JOURNAL OF IMMUNOLOGY | 1996年 / 156卷 / 03期
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The participation of membrane inhibitors in C-mediated inflammation in vivo was analyzed in rats with the use of mAbs against membrane inhibitors of C. 512Ag inhibits C3 convertase of homologous rat C and rat CD59 prevents the formation of homologous membrane attack complexes, The histologic distributions of 512Ag and CD59 in rat skin were essentially the same, However, although intracutaneous administration of mAb against 512Ag (anti-512Ag) in the form of F(ab')(2) induced a remarkable inflammatory response, visualized by exudation of Evans blue that had been previously injected i.v., the mAb against CD59 caused no inflammatory exudate, Furthermore, anti-512Ag F(ab')(2) caused deposition of C3 followed by intense polymorphonuclear leukocyte infiltration and hemorrhage at the injection sites within 24 h, This reaction was completely abrogated by depletion of C. Therefore, spontaneous C activation on self cell membranes requires amplification at the C3 convertase step, which is restricted by membrane inhibitors such as 512Ag, thus preventing inflammation, A type II allergic response might preferentially occur at sites that exhibit an impairment of membrane inhibitor(s) of C3 convertase, However, although depletion of leukocytes by preadministration of cyclophosphamide did not reduce C3 deposition by anti-512Ag, Evans blue exudation was appreciably reduced, indicating that infiltrated leukocytes play a role in enhancing and prolonging inflammation initiated by local C activation.
引用
收藏
页码:1182 / 1188
页数:7
相关论文
共 50 条
  • [41] Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation
    Hasturk, Hatice
    Hajishengallis, George
    Lambris, John D.
    Mastellos, Dimitrios C.
    Yancopoulou, Despina
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (23):
  • [42] Novel antagonist antibody to TLR3 blocks poly(I:C)-induced inflammation in vivo and in vitro
    Bunting, Rachel A.
    Duffy, Karen E.
    Lamb, Roberta J.
    San Mateo, Lani R.
    Smalley, Karen
    Raymond, Holly
    Liu, Xuesong
    Petley, Ted
    Fisher, Jamie
    Beck, Heena
    Flavell, Richard A.
    Alexopoulou, Lena
    Ward, Christine K.
    CELLULAR IMMUNOLOGY, 2011, 267 (01) : 9 - 16
  • [43] C3c as a fluid phase marker for inflammation-generation and characterization of monoclonal antibodies against neoepitopes on activated or inactivated split products of C3
    Skjodt, Mikkel-Ole
    Brandt, Jette
    Vitved, Lars
    MOLECULAR IMMUNOLOGY, 2007, 44 (16) : 3917 - 3918
  • [44] Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy
    Andersen, Camilla Aakaejr
    Marcussen, Niels
    Gregersen, Jon Waarst
    CLINICAL KIDNEY JOURNAL, 2013, 6 (06): : 639 - 642
  • [45] IMMUNOHISTOCHEMICAL ANALYSIS OF CUTANEOUS MALIGNANT-MELANOMA - COMPARISON OF S-100 PROTEIN, HMB-45 MONOCLONAL-ANTIBODY AND NKI/C3 MONOCLONAL-ANTIBODY
    FERNANDO, SSE
    JOHNSON, S
    BATE, J
    PATHOLOGY, 1994, 26 (01) : 16 - 19
  • [46] The monoclonal antibody, 3E7, is a multi-functional inhibitor of the alternative pathway that blocks NeF-triggered activation
    Paixao-Cavalcante, Danielle
    Lindorfer, Margaret A.
    Morgan, B. Paul
    Taylor, Ronald P.
    Harris, Claire L.
    MOLECULAR IMMUNOLOGY, 2010, 47 (13) : 2292 - 2292
  • [47] Noninvasive detection of tuberculosis-associated inflammation with a radioiodinated anti-C3d monoclonal antibody
    Foss, Catherine A.
    Kulik, Liudmila
    Ordonez, Alvaro
    Jain, Sanjay K.
    Pomper, Martin G.
    Holers, V. Michael
    Thurman, Joshua M.
    MOLECULAR IMMUNOLOGY, 2014, 61 (02) : 259 - 259
  • [48] ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY DUE TO MONOCLONAL ANTIBODY AGAINST COMPLEMENT CONTROL PROTEIN FACTOR H
    Andronikidis, Paraskevi Eva
    Vasiliki, Papanikolaou
    Styliani, Plavoukou
    Glykeria, Tsouka
    Sosanna, Delibasi
    Christina, Vourlakou
    Apostolou, Theofanis
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [49] Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases
    Fridkis-Hareli, Masha
    Storek, Michael
    Mazsaroff, Istvan
    Risitano, Antonio M.
    Lundberg, Ante S.
    Horvath, Christopher J.
    Holers, V. Michael
    BLOOD, 2011, 118 (17) : 4705 - 4713
  • [50] INHIBITION OF CLASSIC AND ALTERNATIVE PATHWAY CONVERTASES BY RAT MONOCLONAL-ANTIBODY TO HUMAN-C3
    RUDDY, S
    MOXLEY, GF
    PURKALL, DB
    IMMUNOBIOLOGY, 1983, 164 (3-4) : 291 - 291